Tue, June 26, 2012
Mon, June 25, 2012
[ Mon, Jun 25th 2012 ] - Market Wire
Myths or Factsa" Campaign
Sun, June 24, 2012
Sat, June 23, 2012
Fri, June 22, 2012
Thu, June 21, 2012
Wed, June 20, 2012
Tue, June 19, 2012
Mon, June 18, 2012
Sun, June 17, 2012
Sat, June 16, 2012
Fri, June 15, 2012
Thu, June 14, 2012
Wed, June 13, 2012
Tue, June 12, 2012
Mon, June 11, 2012
Sat, June 9, 2012
Fri, June 8, 2012
Thu, June 7, 2012

Valeant Pharmaceuticals Completes Syndication Of Incremental Term Loans


//health-fitness.news-articles.net/content/2012/ .. letes-syndication-of-incremental-term-loans.html
Published in Health and Fitness on Thursday, June 14th 2012 at 15:40 GMT by Market Wire   Print publication without navigation


Valeant Pharmaceuticals Completes Syndication Of Incremental Term Loans -- MONTREAL, June 14, 2012 /PRNewswire/ --

Valeant Pharmaceuticals Completes Syndication Of Incremental Term Loans

[ ]
[ ]

MONTREAL, June 14, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: [ VRX ] and TSX: VRX) announced today the successful syndication of $600 million of incremental term loans under its existing senior secured credit facilities to be used to fund repayment of amounts outstanding under its existing $275 million revolving facility and for general corporate purposes, including acquisitions.  The incremental term loans will mature in 2019 and have terms that are similar to the Company's existing $600 million Term Loan B facility, with certain modifications. The facility closed on June 14, 2012.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at [ www.valeant.com ].

(Logo: [ http://photos.prnewswire.com/prnh/20101025/LA87217LOGO ])

Contact Information:
Laurie W. Little
949-461-6002
[ laurie.little@valeant.com ]

 

SOURCE Valeant Pharmaceuticals International, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.valeant.com ]


Publication Contributing Sources